Dose EScalation Induction of EvERolimus

NCT02387099 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

156

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
Hormone Receptor Positive Tumor

Interventions

DRUG: 3 weeks Dose Induction of Everolimus
DRUG: 3 weeks Conventional Everolimus Dosing
DRUG: Open Label Phase with conventional 10mg Everolimus Dosing week 4-24
DRUG: Standard Care after 24 weeks

Sponsor

GBG Forschungs GmbH

Collaborators

[object Object]